Enzalutamide restores the testosterone effect on H19 expression in prostate cancer cells but not in exosomes

Aim: Cellular or exosomal expression of an oncofetal lncRNA gene H19, was evaluated during androgen stimulation viadihydrotestosterone (DHT) or androgen receptor (AR) blockage via enzalutamide in cultured hormone-sensitive prostate cancer(PCa) cells which overexpress the androgen receptor (LNCaP-AR+) in the present study.Material and Methods: Cells were treated using DHT (10 nM) and/or enzalutamide (10 uM) for 24 hours. Cellular, and exosomalexpression of H19 was investigated using a quantitative polymerase chain reaction assay.Results: Our findings revealed that the mean cellular H19 expression decreased approximately 2.3 fold after androgen stimulationof PCa cells. Enzalutamide restored DHT effect with AR blockage, and we found increased H19 expression with the combined useof DHT, and enzalutamide compared with the levels in the control cells (p

PDF

___

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
2. Filella X, Foj L. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. Int J Mol Sci 2016;17: pii: E1784
3. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33.
4. de Bono JS, Logothetis CJ, Molina A, et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995- 2005.
5. Tran C, Ouk S, Clegg NJ, et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
6. Hoffman RM. Clinical practice. Screening for prostate cancer. N Engl J Med 2011;365:2013-9.
7. Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015;523:177-82.
8. Tanaka Y, Kamohara H, Kinoshita K, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 2013;119:1159-67.
9. Gezer U, Özgür E, Cetinkaya M, et al. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. Cell Biol Int 2014;38:1076-9.
10. Yoshimoto R, Mayeda A, Yoshida M, et al. MALAT1 long noncoding RNA in cancer. Biochim Biophys Acta 2016;1859:192- 9.
11. Taheri M, Omrani MD, Ghafouri-Fard S. Long non-coding RNA expression in bladder cancer. Biophys Rev 2017;8:1205-13.
12. Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014;25:666-81.
13. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464:1071–6.
14. Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 2013;45:1392–8.
15. Hung CL, Wang LY, Yu YL, et al. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A 2014;111:18697–702.
16. Cheng W, Zhang Z, Wang J. Long noncoding RNAs: new players in prostate cancer. Cancer Lett 2013;339:8-14.
17. Brannan CI, Dees EC, Ingram RS, et al. The product of the H19 gene may function as an RNA. Mol Cell Biol 1990;10:28- 36.
18. Yoshimizu T, Miroglio A, Ripoche MA, et al. The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci U S A 2008;105:12417-22.
19. Yang F, Bi J, Xue X, et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J 2012;279:3159-65.
20. Kallen AN, Zhou XB, Xu J, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell 2013;52:101-12.
21. Zhu M, Chen Q, Liu X, et al. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. FEBS J 2014;281:3766-75.
22. Berteaux N, Lottin S, Adriaenssens E, et al. Hormonal regulation of H19 gene expression in prostate epithelial cells. J Endocrinol 2004;183:69-78.
23. Conigliaro A, Costa V, Lo Dico A, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015;14:155.
24. Dugimont T, Montpellier C, Adriaenssens E, et al. The H19 TATA- less promoter is efficiently repressed by wildtype tumor suppressor gene product p53. Oncogene 1998;16:2395-401.
25. Park IY, Sohn BH, Choo JH, et al. Deregulation of DNA methyltransferases and loss of parental methylation at the insulin-like growth factor II (Igf2)/H19 loci in p53 knockout mice prior to tumor development. J Cell Biochem 2005;94:585-96.
26. Yu S, Cao H, Shen B, et al. Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget 2015;6:37151-68.
27. Taneja SS. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. J Urol 2015;193:538.